These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 4113183)

  • 21. Regression of prostatic hypertrophy by osaterone acetate in dogs.
    Tsutsu T; Hori T; Shimizu M; Orima H; Kawakami E; Fukuda S
    J Vet Med Sci; 2000 Oct; 62(10):1115-9. PubMed ID: 11073087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism].
    Iguchi H; Ikeuchi T; Kai Y; Yoshida H
    Hinyokika Kiyo; 1994 Mar; 40(3):215-9. PubMed ID: 7513937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on the endocrine properties of a new progestational steroid 4,6-dichloro-16-methylene-17-hydroxy-4,6-pregnadiene-3,20-dione 17-acetate (MDAP).
    Boris A; DeMartino L; Trmal T
    Steroids; 1971 Oct; 18(4):399-410. PubMed ID: 4110091
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of osaterone acetate administration on prostatic regression rate, peripheral blood hormone levels and semen quality in dogs with benign prostatic hypertrophy.
    Tsutsui T; Hori T; Shimizu M; Tatsuzawa C; Kawakami E
    J Vet Med Sci; 2001 Apr; 63(4):453-6. PubMed ID: 11346183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical evaluation of chlormadinone acetate (CMA) in benign prostatic hypertrophy (author's transl)].
    Fujisawa S; Fujii M; Yasui H; Koshito K; Kamiryo Y
    Horumon To Rinsho; 1981 Nov; 29(11):1389-94. PubMed ID: 6176374
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical evaluation of the long-term treatment with chlormadinone acetate in patients with benign prostatic hypertrophy].
    Kogawa T; Yanagiya H; Takashima T; Higashino I; Kudo T; Suzuki T; Mikuni T; Kido K; Tsukui A; Yagihashi Y
    Hinyokika Kiyo; 1993 Mar; 39(3):281-7. PubMed ID: 7685143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Fundamental and clinical study on antiandrogens--androgen-dependency of prostatic tumors and clinical application of antiandrogens (author's transl)].
    Shida K
    Horumon To Rinsho; 1980 Aug; 28(8):899-928. PubMed ID: 6161722
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of progestational agents on gonadal and adrenal cortical function in patients with benign prostatic hypertrophy and carcinoma of the prostate.
    Geller J; Fruchtman B; Meyer C; Newman H
    J Clin Endocrinol Metab; 1967 Apr; 27(4):556-60. PubMed ID: 4164338
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
    Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
    Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Steroidal Antiandrogen or 5-alpha-reductase Inhibitor on Prostate Tissue Hormone Content.
    Shibata Y; Arai S; Miyazawa Y; Shuto T; Nomura M; Sekine Y; Koike H; Matsui H; Ito K; Suzuki K
    Prostate; 2017 May; 77(6):672-680. PubMed ID: 28145028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].
    Kanimoto Y; Okada K
    Hinyokika Kiyo; 1991 Nov; 37(11):1423-8. PubMed ID: 1722627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of osaterone acetate on clinical signs and prostate volume in dogs with benign prostatic hyperplasia.
    Socha P; Zduńczyk S; Tobolski D; Janowski T
    Pol J Vet Sci; 2018 Dec; 21(4):559-566. PubMed ID: 30605276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Androgenic and anti-gonadal activities of chlormadinone in the rat].
    Chambon Y; Le Vève Y; Gourvès M
    C R Seances Soc Biol Fil; 1966; 160(8):1720-4. PubMed ID: 4167486
    [No Abstract]   [Full Text] [Related]  

  • 34. Short-term oral treatment of canine benign prostatic hypertrophy with chlormadinone acetate.
    Orima H; Shimizu M; Tsutsui T; Kawakami E; Ogasa A
    J Vet Med Sci; 1995 Feb; 57(1):139-41. PubMed ID: 7538794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chlormadinone acetate pellet implantation plus short-term oral administration in dogs with benign prostatic hypertrophy.
    Kawakami E; Shimizu M; Orima H; Fujita M; Hori T; Tsutsui T
    Int J Androl; 1998 Apr; 21(2):67-73. PubMed ID: 9675615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: a retrospective multi-institutional study.
    Fujimoto K; Hirao Y; Masumori N; Arai Y; Yamanaka H; Kato T; Miyazawa K
    Int J Urol; 2006 May; 13(5):543-9. PubMed ID: 16771723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of prostatic hypertrophy with progestational steroid (gestonorone caproate)].
    Tanaka H; Fukushige M; Shiraishi T
    Hinyokika Kiyo; 1970 Sep; 16(9):531-50. PubMed ID: 4097365
    [No Abstract]   [Full Text] [Related]  

  • 38. [Application of antiandrogens on prostatic diseases].
    Takahashi S; Hasegawa F; Isurugi K
    Nihon Rinsho; 1994 Mar; 52(3):809-14. PubMed ID: 7513031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of prostatic hypertrophy with 19-norhydroxyprogesterone caproate].
    Kato T; Okada K
    Hinyokika Kiyo; 1970 Sep; 16(9):489-500. PubMed ID: 4097361
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of oral administration of chlormadinone acetate on canine prostatic hypertrophy.
    Kawakami E; Tsutsui T; Shimizu M; Orima H; Makanae Y; Yajima K; Ogasa A
    J Vet Med Sci; 1993 Aug; 55(4):631-5. PubMed ID: 7691191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.